Fuad Mirzayev
Overview
Explore the profile of Fuad Mirzayev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lienhardt C, Dooley K, Nahid P, Wells C, Ryckman T, Kendall E, et al.
Bull World Health Organ
. 2024 Jul;
102(8):600-607.
PMID: 39070602
Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target...
2.
Ryckman T, Schumacher S, Lienhardt C, Sweeney S, Dowdy D, Mirzayev F, et al.
Lancet Glob Health
. 2024 May;
12(6):e995-e1004.
PMID: 38762299
Background: With numerous trials investigating novel drug combinations to treat tuberculosis, we aimed to evaluate the extent to which future improvements in tuberculosis treatment regimens could offset potential increases in...
3.
Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, Nguyen L, et al.
Clin Infect Dis
. 2024 Mar;
78(6):1698-1706.
PMID: 38525535
Background: In 2019, the South African tuberculosis program replaced ethionamide with linezolid as part of an all-oral 9-month regimen. We evaluated treatment outcomes for patients assigned to regimens including linezolid...
4.
Dheda K, Mirzayev F, Cirillo D, Udwadia Z, Dooley K, Chang K, et al.
Nat Rev Dis Primers
. 2024 Mar;
10(1):22.
PMID: 38523140
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public...
5.
Hasan T, Medcalf E, Nyangwa B, Egizi E, Berry C, Dodd M, et al.
Clin Infect Dis
. 2023 Oct;
78(3):730-741.
PMID: 37874021
Background: Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with...
6.
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, et al.
Nat Commun
. 2023 Oct;
14(1):6182.
PMID: 37794037
In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case...
7.
Olaru I, Beliz Meier M, Mirzayev F, Prodanovic N, Kitchen P, Schumacher S, et al.
EClinicalMedicine
. 2023 Apr;
58:101938.
PMID: 37090436
Background: There is a substantial overlap in the epidemiology of chronic hepatitis B (HBV), hepatitis C (HCV) and tuberculosis (TB) due to overlapping risk factors. Testing for viral hepatitis is...
8.
Gupta A, Juneja S, Sahu S, Yassin M, Brigden G, Wandwalo E, et al.
PLOS Glob Public Health
. 2023 Mar;
2(11):e0001287.
PMID: 36962626
No abstract available.
9.
P Solans B, Beranger A, Radtke K, Mohamed A, Mirzayev F, Gegia M, et al.
Clin Infect Dis
. 2023 Jan;
76(9):1658-1670fc.
PMID: 36609692
Background: Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization-recommended or...
10.
Masini T, Kanchar A, Mirzayev F, Viney K, Yedilbayev A, Zignol M, et al.
Eur Respir J
. 2022 Jul;
60(2).
PMID: 35777762
No abstract available.